---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-096656"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:54:32.185536+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics appoints Michael A. Jerman as director, effective July 15, 2025

## Summary
- Jerman fills vacancy from Dale Curtis Hogue's resignation; also joins Audit and Compensation Committees.
- Jerman replaces Holger Weis on committees after Weis became CEO; Jerman will chair Audit Committee.
- Compensation: $40k annual cash retainer, plus committee fees; initial option for 10,000 shares vesting over 36 months.
- Prorated annual grant of 3,200 shares awarded; vesting subject to continued service through 2026 annual meeting.

## SEC filing metadata
- accession: 0000950170-25-096656
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000095017025096656/0000950170-25-096656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000095017025096656/tcrt-20250715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-096656
- JSON: https://secwatch.observer/filing/0000950170-25-096656.json
- Plain text: https://secwatch.observer/filing/0000950170-25-096656.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.